FDA and Aetion announced they will use Aetion’s Evidence Platform to gather real-world evidence on inpatient COVID-19 therapies, with the goal of demonstrating how a platform-based approach can help advance regulatory knowledge on the use of RWE and also to provide a scalable infrastructure through which therapies for coronavirus and other future infectious diseases and pandemics can be rapidly developed and evaluated. FDA and Aetion’s contract will support the agency’s broader digital transformation efforts, which include its Technology and Data...